Agilent Technologies Inc. - A STOCK NEWS

Agilent Technologies Inc. (NYSE: A) has joined the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC), highlighting its commitment to enhancing biopharmaceutical manufacturing processes. This partnership aims to advance analytical tools and solutions critical for biotherapeutics and gene therapy. Senior VP Darlene Solomon emphasized the need for improved biomanufacturing efficiencies. Agilent's innovations in automation, machine learning, and real-time analytics will support these efforts, contributing to lower costs and improved bioprocessing efficiency in the biopharmaceutical sector.

Arima Genomics, Inc. has successfully closed a $7 million Series B Preferred Stock financing round, with participation from both new and existing investors, including Genetron Health and Agilent Technologies. The funds aim to accelerate innovation and expand the company’s capabilities in 3D genomics, which provides crucial insights into the structure of genomes, enhancing research and therapeutic development. Arima's technologies are increasingly recognized in precision oncology, with over 600 global customers and more than 200 peer-reviewed studies leveraging its products.

Agilent Technologies Inc. (NYSE: A) announced Dr. Federica Fiorini as the recipient of the 2022 Darlene Solomon Award, recognizing her research in metabolomics. The award was presented at the iSLS10 symposium in Singapore on March 8-10. Dr. Fiorini will gain exposure through financial support for attending mass spectrometry conferences and working at Agilent's Global Solutions Development Center. The award aims to empower early-career female scientists and promote innovative research in lipidomics. Dr. Fiorini expressed gratitude and enthusiasm for advancing her field.

Edwards, a leader in semiconductor supply, is investing in a new 200,000-square-foot manufacturing facility in Chandler, Arizona. This facility will utilize advanced technologies to support the growing semiconductor market, creating approximately 200 jobs locally. With construction underway, the site will begin operations in Q3, focusing on the remanufacturing and assembly of vacuum pump equipment essential for semiconductor fabrication. This investment underlines Edwards' commitment to sustainable practices and enhancing supply chain capacity in North America.

Agilent Technologies Inc. (NYSE: A) announced that CFO Bob McMahon will participate in Q&A sessions at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 11:10 a.m. EST, and the Barclays Global Health Care Conference on March 16, 2022, at 2:05 p.m. EDT. Both events will be webcast live, with access links available prior to the sessions on Agilent's Investor Relations website. Agilent is a leader in life sciences and diagnostic markets, generating $6.32 billion in revenue in fiscal 2021.

Agilent Technologies Inc. (NYSE: A) and the University of Vermont (UVM) have launched the Agilent Laboratory for Chemical Analysis (ALCA) in Santa Clara, California, and Burlington, Vermont. This facility aims to advance research in chemical composition and structure, benefiting students, academic staff, and regional businesses. The laboratory will provide state-of-the-art instrumentation and act as a technology resource for local start-ups. Agilent's commitment to science and local community support is emphasized by its investment in this innovative educational space.

Agilent Technologies Inc. (NYSE: A) and QIMR Berghofer Medical Research Institute have developed a novel COVID-19 saliva testing method using the Agilent Cary 630 FTIR Spectrometer. This proof-of-concept study analyzes the body's immune response rather than detecting the virus, making it potentially more effective against mutations. The research highlights the simplicity and rapidity of the method, which requires minimal equipment and provides results in seconds. Published in the journal Biomedicines, the study underscores the Cary 630's suitability for various settings, enhancing COVID-19 diagnostics.

Agilent Technologies reported a strong start to 2022, with revenue of $1.67 billion, marking an 8% growth year-over-year and 9% growth on a core basis. GAAP net income was $283 million with EPS of $0.93, consistent with the same period last year. The company raised its full-year revenue outlook to $6.67 billion to $6.73 billion, reflecting 5.6% to 6.5% growth. Non-GAAP EPS guidance was increased to $4.80 to $4.90. Agilent attributed its performance to a strong order book and confident management outlook.

Agilent Technologies Inc. (NYSE: A) has acquired advanced AI technology from Virtual Control. This technology, known as ACIES, will enhance Agilent's gas chromatography/mass spectrometry (GC/MS) platforms, improving efficiency and accuracy in lab workflows. The acquisition includes software and assets, with core ACIES team members joining Agilent. The integration is expected to benefit multiple sectors, including food testing and environmental applications, and aims to elevate lab productivity through innovative digital solutions.